Ken LeClair is VP of Technical Development and Manufacturing at TScan.  Prior to TScan, Ken spent 2 years leading the manufacturing team at Editas Medicine, and 8 years at Novartis, where he focused first on developability assessments for biologics candidates, then on tech transferring the UPenn CAR T immunotherapy technology to Novartis and to selected CMOs, which led to the first FDA-approved autologous CAR T cell therapy.  Prior to leaving academia for industry, Ken was an Assistant Professor in the Division of Immunology of Beth Israel Deaconess Medical Center at the Harvard Med School. Ken received an A.B. in Biology from Bowdoin College and a Ph.D. in Immunobiology from Yale University, and was a postdoc in Phil Sharp’s lab at the MIT Center for Cancer Research.

Away from TScan, Ken thoroughly enjoys all kinds of home improvement projects, spending time at Nantasket Beach and often commutes to work by bike and commuter boat.